{
    "info": {
        "nct_id": "NCT03489343",
        "official_title": "A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas",
        "inclusion_criteria": "* Male or female patients, ≥ 18 years of age at the time of obtaining informed consent.\n* Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.\n* Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or nonresectability of the tumor.\n* Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.\n* Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n* Not of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug. Women of childbearing potential (WOCBP) and fertile men with WOCBP-partner(s) not using and not willing to use a highly effective method of contraception.\n* Known, untreated central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.\n* Hematologic malignancies other than lymphomas.\n* Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable.\n* Active uncontrolled bleeding or a known bleeding diathesis.\n* Clinically significant cardiovascular disease or condition.\n* Significant ocular disease or condition, including history of autoimmune or inflammatory disorder.\n* Significant pulmonary disease or condition.\n* Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.\n* An active, known, or suspected autoimmune disease, or a documented history of autoimmune disease or syndrome, requiring systemic steroids or other immunosuppressive medications.\n* History of significant toxicities associated with previous administration of immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy.\n* Patients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy, with exceptions.\n* Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.\n* Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.",
            "criterions": [
                {
                    "exact_snippets": "Refractory to ... existing therapy(ies) known to provide clinical benefit",
                    "criterion": "response to existing therapies known to provide clinical benefit",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "intolerant of existing therapy(ies) known to provide clinical benefit",
                    "criterion": "tolerance to existing therapies known to provide clinical benefit",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male or female patients, ≥ 18 years of age at the time of obtaining informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Male or female patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.",
            "criterions": [
                {
                    "exact_snippets": "Documented (histologically- or cytologically-proven) solid tumor malignancy",
                    "criterion": "solid tumor malignancy",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "histologically-proven",
                                "cytologically-proven"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "solid tumor malignancy that is locally advanced or metastatic",
                    "criterion": "solid tumor malignancy stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with documented lymphomas",
                    "criterion": "lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or nonresectability of the tumor.",
            "criterions": [
                {
                    "exact_snippets": "Malignancy (solid tumor or lymphoma)",
                    "criterion": "malignancy type",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "solid tumor",
                                "lymphoma"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "currently not amenable to surgical intervention",
                    "criterion": "amenability to surgical intervention",
                    "requirements": [
                        {
                            "requirement_type": "amenability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "due to either medical contraindications or nonresectability of the tumor",
                    "criterion": "reason for non-amenability to surgery",
                    "requirements": [
                        {
                            "requirement_type": "reason",
                            "expected_value": [
                                "medical contraindications",
                                "nonresectability of the tumor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Not of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Not of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "use period",
                            "expected_value": "beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.",
            "criterions": [
                {
                    "exact_snippets": "Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": [
                                "measurable",
                                "non-measurable"
                            ]
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": [
                                "RECIST v1.1",
                                "RECIL 2017"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Active uncontrolled bleeding or a known bleeding diathesis.",
            "criterions": [
                {
                    "exact_snippets": "Active uncontrolled bleeding",
                    "criterion": "bleeding",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "known bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy, with exceptions.",
            "criterions": [
                {
                    "exact_snippets": "unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy",
                    "criterion": "toxicity from prior antineoplastic therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "resolution_status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant ocular disease or condition, including history of autoimmune or inflammatory disorder.",
            "criterions": [
                {
                    "exact_snippets": "Significant ocular disease or condition",
                    "criterion": "ocular disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of autoimmune or inflammatory disorder",
                    "criterion": "autoimmune or inflammatory disorder",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* An active, known, or suspected autoimmune disease, or a documented history of autoimmune disease or syndrome, requiring systemic steroids or other immunosuppressive medications.",
            "criterions": [
                {
                    "exact_snippets": "An active, known, or suspected autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "a documented history of autoimmune disease or syndrome",
                    "criterion": "autoimmune disease or syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring systemic steroids or other immunosuppressive medications",
                    "criterion": "requirement for systemic steroids or other immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "requirement for medication",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "medication type",
                            "expected_value": [
                                "systemic steroids",
                                "other immunosuppressive medications"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known, untreated central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.",
            "criterions": [
                {
                    "exact_snippets": "Known, untreated central nervous system (CNS) or leptomeningeal metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known, untreated ... leptomeningeal metastases",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "spinal cord compression",
                    "criterion": "spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug. Women of childbearing potential (WOCBP) and fertile men with WOCBP-partner(s) not using and not willing to use a highly effective method of contraception.",
            "criterions": [
                {
                    "exact_snippets": "Women who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "intending to become pregnant before, during, or within 6 months after the last dose of study drug",
                    "criterion": "pregnancy intention",
                    "requirements": [
                        {
                            "requirement_type": "intention to become pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP) and fertile men with WOCBP-partner(s) not using and not willing to use a highly effective method of contraception",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "use of highly effective contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of significant toxicities associated with previous administration of immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy.",
            "criterions": [
                {
                    "exact_snippets": "History of significant toxicities associated with previous administration of immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy.",
                    "criterion": "toxicities from immune checkpoint inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "association",
                            "expected_value": "previous administration of immune checkpoint inhibitors"
                        },
                        {
                            "requirement_type": "consequence",
                            "expected_value": "necessitated permanent discontinuation of that therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable.",
            "criterions": [
                {
                    "exact_snippets": "Active thrombosis",
                    "criterion": "thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1)",
                    "criterion": "history of DVT or PE",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "event_type",
                            "expected_value": [
                                "deep vein thrombosis",
                                "pulmonary embolism"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unless adequately treated and considered stable",
                    "criterion": "treatment and stability of DVT or PE",
                    "requirements": [
                        {
                            "requirement_type": "adequate treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant pulmonary disease or condition.",
            "criterions": [
                {
                    "exact_snippets": "Significant pulmonary disease or condition.",
                    "criterion": "pulmonary disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant cardiovascular disease or condition.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease or condition",
                    "criterion": "cardiovascular disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hematologic malignancies other than lymphomas.",
            "criterions": [
                {
                    "exact_snippets": "Hematologic malignancies other than lymphomas",
                    "criterion": "hematologic malignancies (excluding lymphomas)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).",
            "criterions": [
                {
                    "exact_snippets": "Known history of human immunodeficiency virus (HIV)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active infection with hepatitis B virus (HBV)",
                    "criterion": "hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active infection with ... hepatitis C virus (HCV)",
                    "criterion": "hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "active infection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.",
            "criterions": [
                {
                    "exact_snippets": "Inadequate recovery from any prior surgical procedure",
                    "criterion": "recovery from prior surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "having undergone any major surgical procedure within 4 weeks prior to C1/D1",
                    "criterion": "major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.",
            "criterions": [
                {
                    "exact_snippets": "Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.",
                    "criterion": "gastrointestinal (GI) disease or condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "significance",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}